|
biomedicina slovenica |
pr=Chatzidionysiou : 22
-
Courvoisier Delphine S.; Chatzidionysiou Katarina; Mongin Denis; Lauper Kim; Mariette Xavier; Morel Jacques; Gottenberg Jacques-Eric; Bergstra Sytske Anne; Pombo-Suarez Manuel; Rotar Žiga
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents
2020 ►
-
Chatzidionysiou Katerina; Lukina Galina; Gabay Cem; Hetland Merete L.; Hauge Ellen Margrethe; Pavelka Karel; Nordström Dan C.; Canhao Helena; Tomšič Matija; Rotar Žiga
Smoking and response to rituximab in rheumatoid arthritis
2018 ►
-
Chatzidionysiou Katerina; Lie Elisabeth; Lukina Galina; Hetland Merete L.; Hauge Ellen Margrethe; Pavelka Karel; Gabay Cem; Scherer Almut; Tomšič Matija; Rotar Žiga
Rituximab retreatment in rheumatoid arthritis in a real-life cohort
2017 ►
-
Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgen; Lukina Galina; Lund Hetland Merete; Tarp Ulrik; Ancuta Ioan; Pavelka Karel; Nordström Dan C.; Tomšič Matija
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort
2016 ►
-
Gabay Cem; Riek Myriam; Lund Hetland Merete; Hauge Ellen Margrethe; Pavelka Karel; Tomšič Matija; Canhao Helena; Chatzidionysiou Katerina; Lukina Galina; Nordström Dan C.
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis
2016 ►
-
Walker Ulrich A; Jaeger Veronika K.; Chatzidionysiou Katerina; Hetland Merete L.; Hauge Ellen Margrethe; Pavelka Karel; Nordström Dan C.; Canhao Helena; Tomšič Matija; Van Vollenhoven Ronald F.; Gabay Cem
Rituximab done
2016 ►
-
Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgen; Lukina Galina; Hetland Merete L.; Hauge Ellen Margrethe; Pavelka Karel; Gabay Cem; Nordström Dan C.; Canhao Helena; Tomšič Matija
Smoking and response to rituximab in anti-CCP positive and negative rheumatoid arthritis
2015 ►
-
Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgen; Lukina Galina; Lund Hetland Merete; Hauge Ellen Margrethe; Pavelka Karel; Gabay Cem; Nordström Dan C.; Tomšič Matija
Smoking and response to Rituximab in Anti-CCP positive and negative rheumatoid arthritis - results from an International European Collaboration
2014 ►
-
Walker Ulrich A; Jaeger Veronika K.; Chatzidionysiou Katerina; Lund Hetland Merete; Hauge Ellen Margrethe; Pavelka Karel; Nordström Dan C.; Canhao Helena; Tomšič Matija; Van Vollenhoven Ronald F.
Rituximab Done! What's Next in RA?
2014 ►
-
Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgen; Pavelka Karel; Tomšič Matija
Fixed versus on-flare retreatment with rituximab in RA - results from the cererra collaboration
2014 ►
-
Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgen; Tomšič Matija
Effectiveness of repeated courses of Rituximab in RA - results from the cererra collaboration
2013 ►
-
Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgen; Tomšič Matija
Fixed versus on-flare retreatment with Rituximab In RA-results from the cererra collaboration
2013 ►
-
Chatzidionysiou K; Lie E; Nasonov E; Tomšič M
Efficacy of different doses of rituximab for the treatment or RA: data from CERERRA colaboration
2012 ►
-
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Lund-Hetland M; Trap U; Gabay C; van Riel P; Nordstroem D; Tomšič M
Retreatment with Rituximab yields better clinical outcomes, especially when it is given at fixed interval: data from the Cererra collaboration
2011 ►
-
Chatzidionysiou K; Lie E; Nasonov E; Lukina G; Lund-Hetland M; Tarp U; Gabay C; van Riel P; Nordstroem D; Tomšič M
Seropositivity, and in particular ACPA positivity is a strong predictor of response to treatment with Rituximab: pooled data from 10 European registries
2011 ►
-
Gabay C; Chatzidionysiou K; Nasonov E; Lukina G; Hetland ML; Tarp U; van Riel PL; Nordstrom D; Gomez-Reino J; Tomšič M
Effectiveness of different DMARD co-therapies in Rituximab - treated rheumatoid arthritis (RA) patients - results of a one-year follow up study from Cerrera collaboration
2010 ►
-
Chatzidionysiou K; van Vollenhoven RF; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PLCM; Nordsroem DC; Tomšič M
Efficacy of Rituximab retreatment in clinical practice: data from the Cererra collaboration
2010 ►
-
van Vollenhoven RF; Chatzidionysiou K; Nasonov E; Lukina G; Hetland ML; Tarp U; Gabay C; van Riel PPLC; Nordstroem DC; Tomšič M
Characterisation of RA patients not requiring retreatment with Rituximab within 12 months after the first course - a Cererra study
2010 ►
-
Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgeny; Lukina Galina; Hetland Merete Lund; Tarp Ulrik; van Riel Piet LCM; Nordstrom Dan C; Gomez-Reino Juan; Tomšič Matija
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
2012 ►
-
Chatzidionysiou Katerina; Lie Elisabeth; Nasonov Evgeny; Tomšič Matija
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
2011 ►
-
van Vollenhoven Ronald; Chatzidionysiou K; Nasonov E; Tomšič M
Six-month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA). Efficacy of rituximab is highest in RF-positive patients and in those who failed at most one prior anti-TNF
2009 ►
-
van Vollenhoven RF; Chatzidionysiou K; Gabay C; Tomšič M
Rheumatoid factor predicts response to rituximab in a European registry-based cohort: 6-month results from the collaborative European registries for rituximab in rheumatoid arthritis (CERERRA)
2009 ►
New search
Comments
Top of page
Institute for Biostatistics and Medical Informatics